Yuanfang Ma

4.2k total citations
141 papers, 3.4k citations indexed

About

Yuanfang Ma is a scholar working on Molecular Biology, Immunology and Epidemiology. According to data from OpenAlex, Yuanfang Ma has authored 141 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Molecular Biology, 47 papers in Immunology and 25 papers in Epidemiology. Recurrent topics in Yuanfang Ma's work include Cell death mechanisms and regulation (16 papers), Liver Diseases and Immunity (12 papers) and Liver Disease Diagnosis and Treatment (12 papers). Yuanfang Ma is often cited by papers focused on Cell death mechanisms and regulation (16 papers), Liver Diseases and Immunity (12 papers) and Liver Disease Diagnosis and Treatment (12 papers). Yuanfang Ma collaborates with scholars based in China, United Kingdom and United States. Yuanfang Ma's co-authors include Yanzhang Li, Yanfeng Gao, Dongdong Wu, Lixiang Chen, Yuanming Qi, Bing Shen, Ning Guo, Diego Vergani, Liang Guo and Meiru Hu and has published in prestigious journals such as The Journal of Immunology, Gastroenterology and PLoS ONE.

In The Last Decade

Yuanfang Ma

135 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yuanfang Ma China 34 1.6k 783 590 571 364 141 3.4k
Min Zhu China 35 1.6k 1.0× 1.1k 1.4× 316 0.5× 756 1.3× 457 1.3× 127 4.2k
Jun Wu China 30 1.7k 1.1× 566 0.7× 543 0.9× 398 0.7× 405 1.1× 155 3.5k
Guoxiong Xu China 31 1.8k 1.1× 391 0.5× 561 1.0× 434 0.8× 326 0.9× 145 3.5k
Nengtai Ouyang United States 29 1.8k 1.2× 569 0.7× 690 1.2× 294 0.5× 338 0.9× 85 3.5k
Jialan Shi United States 35 2.0k 1.3× 1.4k 1.8× 356 0.6× 444 0.8× 271 0.7× 116 4.4k
Caroline Wheeler‐Jones United Kingdom 37 1.5k 1.0× 484 0.6× 254 0.4× 413 0.7× 558 1.5× 131 3.9k
Kenji Imai Japan 35 1.6k 1.0× 444 0.6× 448 0.8× 898 1.6× 403 1.1× 157 4.0k
Shiro Takahara Japan 38 1.6k 1.0× 509 0.7× 575 1.0× 543 1.0× 968 2.7× 193 4.4k
Yan Huang China 29 1.3k 0.8× 378 0.5× 304 0.5× 423 0.7× 501 1.4× 88 2.7k
Shuxia Wang China 33 1.9k 1.2× 691 0.9× 1.2k 2.1× 476 0.8× 603 1.7× 154 4.7k

Countries citing papers authored by Yuanfang Ma

Since Specialization
Citations

This map shows the geographic impact of Yuanfang Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuanfang Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuanfang Ma more than expected).

Fields of papers citing papers by Yuanfang Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuanfang Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuanfang Ma. The network helps show where Yuanfang Ma may publish in the future.

Co-authorship network of co-authors of Yuanfang Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Yuanfang Ma. A scholar is included among the top collaborators of Yuanfang Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuanfang Ma. Yuanfang Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jing, Jing, Yuting Ma, Wenqing Qi, et al.. (2025). Metformin Ameliorates Ulcerative Colitis Through Inhibiting NLRP3 Inflammasome Activation. Journal of Inflammation Research. Volume 18. 1773–1786. 2 indexed citations
2.
3.
Li, Peiyao, et al.. (2023). Tim-3 protects against cisplatin nephrotoxicity by inhibiting NF-κB-mediated inflammation. Cell Death Discovery. 9(1). 218–218. 10 indexed citations
4.
Li, Ningning, Qiang Fu, Wenying Deng, et al.. (2020). 160P Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology. 31. S1302–S1302. 4 indexed citations
5.
Wang, Wei, Qingzhu Shi, Li Ge, et al.. (2017). Negative regulation of Nod‐like receptor protein 3 inflammasome activation by T cell Ig mucin‐3 protects against peritonitis. Immunology. 153(1). 71–83. 23 indexed citations
6.
Wang, Wendie, Zhi Wen, Wenbin Ji, & Yuanfang Ma. (2015). RACK1 expression contributes to JNK activity, but JNK activity does not enhance RACK1 expression in hepatocellular carcinoma SMMC-7721 cells. Oncology Letters. 9(6). 2767–2770. 7 indexed citations
7.
Wang, Wei, Yan Zhang, Ming Lv, et al.. (2014). Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3. Journal of Ovarian Research. 7(1). 103–103. 7 indexed citations
8.
Si, Yanmin, et al.. (2014). The tetravalent anti-DR5 antibody without cross-linking direct induces apoptosis of cancer cells. Biomedicine & Pharmacotherapy. 70. 41–45. 13 indexed citations
9.
Shi, Ming, Meiru Hu, Dan Liu, et al.. (2012). β2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes. International Journal of Cardiology. 167(4). 1570–1577. 22 indexed citations
10.
Wei, Yinxiang, Yuanfang Ma, Qing Zhao, et al.. (2012). New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib. Molecular Cancer Therapeutics. 11(8). 1693–1702. 40 indexed citations
11.
Vijay, Godhev K. Manakkat, R.D. Abeles, Stephen Ramage, et al.. (2012). PMO-125 Neutrophil intracellular toll-like receptor (TLR) 9 expression serves as a biomarker that determines presence and severity of encephalopathy in acute liver failure and cirrhosis. Gut. 61(Suppl 2). A123.3–A124. 4 indexed citations
12.
Grant, Charlotte R., Rodrigo Liberal, Beth Holder, et al.. (2012). PMO-114 Low CD39 expression marks severe regulatory t cell impairment in patients with autoimmune sclerosing cholangitis. Gut. 61(Suppl 2). A119.1–A119.
13.
Wang, Jing, Shulian Li, Guangchao Liu, et al.. (2011). A Novel Agonistic Anti-Human Death Receptor 5 Monoclonal Antibody with Tumoricidal Activity Induces Caspase- and Mitochondrial-Dependent Apoptosis in Human Leukemia Jurkat Cells. Cancer Biotherapy and Radiopharmaceuticals. 26(2). 143–152. 6 indexed citations
14.
Longhi, Maria Serena, et al.. (2011). P15 Multiple defects of the immunoregulatory system contribute to the development of autoimmune hepatitis. Gut. 60(Suppl 2). A7.2–A7. 1 indexed citations
15.
Wang, Yugang, et al.. (2009). The Construction and Expression of a Novel Chimeric Anti-DR5 Antibody. Hybridoma. 28(2). 101–105. 4 indexed citations
16.
Liu, Guangchao, Jun Zhang, Shigui Liu, et al.. (2009). Detachment of esophageal carcinoma cells from extracellular matrix causes relocalization of death receptor 5 and apoptosis. World Journal of Gastroenterology. 15(7). 836–836. 5 indexed citations
17.
Han, Lu, Ming Shi, Mingli Wang, et al.. (2008). In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16. Cancer Biology & Therapy. 7(11). 1744–1750. 8 indexed citations
18.
Wang, Yihui, et al.. (2001). [Effects of Rholida on the free radical metabolism and serum creatine kinase after exercise at plateau].. PubMed. 14(6). 448–51. 2 indexed citations
19.
Ma, Yuanfang, William Bosron, Giorgina Mieli‐Vergani, & Diego Vergani. (1995). 100 ALCOHOL DEHYDROGENASE. Journal of Pediatric Gastroenterology and Nutrition. 20(4). 470–470. 2 indexed citations
20.
Muratori, Luigi, Marco Lenzi, Yuanfang Ma, et al.. (1995). Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease.. Gut. 37(3). 406–412. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Min Zhu Breakdown of academic impact, for papers by Jun Wu Breakdown of academic impact, for papers by Guoxiong Xu Breakdown of academic impact, for papers by Nengtai Ouyang Breakdown of academic impact, for papers by Jialan Shi Breakdown of academic impact, for papers by Caroline Wheeler‐Jones Breakdown of academic impact, for papers by Kenji Imai Breakdown of academic impact, for papers by Shiro Takahara Breakdown of academic impact, for papers by Yan Huang Breakdown of academic impact, for papers by Shuxia Wang
Rankless by CCL
2026